5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Gastrointestinal O
perforation O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
known O
or O
suspected O
lesions O
of O
the O
GI O
tract O
. O

Monitor O
for O
severe O
, O
persistent O
or O
worsening O
abdominal O
pain O
; O
discontinue O
if O
development O
of O
symptoms O
( O
5.1 O
) O
* O
Opioid O
withdrawal O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
disruptions O
to O
the O
blood-brain O
barrier O
. O

Monitor O
for O
symptoms O
of O
opioid O
withdrawal O
( O
5.2 O
) O
5.1 O
Gastrointestinal O
Perforation O
Cases O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
have O
been O
reported O
with O
use O
of O
another O
peripherally O
acting O
opioid O
antagonist O
in O
patients O
with O
conditions O
that O
may O
be O
associated O
with O
localized O
or O
diffuse O
reduction B-Not_AE_Candidate
of I-Not_AE_Candidate
structural I-Not_AE_Candidate
integrity I-Not_AE_Candidate
in I-Not_AE_Candidate
the I-Not_AE_Candidate
wall I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
( O
e.g. O
, O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
Ogilvie B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
diverticular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
infiltrative B-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
malignancies I-Not_AE_Candidate
or O
peritoneal B-Not_AE_Candidate
metastases I-Not_AE_Candidate
) O
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
MOVANTIK O
in O
patients O
with O
these O
conditions O
or O
other O
conditions O
which O
might O
result O
in O
impaired B-NonOSE_AE
integrity I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
gastrointestinal I-NonOSE_AE
tract I-NonOSE_AE
wall I-NonOSE_AE
( O
e.g. O
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
) O
. O

Monitor O
for O
the O
development O
of O
severe O
, O
persistent O
or O
worsening O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
; O
discontinue O
MOVANTIK O
in O
patients O
who O
develop O
this O
symptom O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.2 O
Opioid O
Withdrawal O
Clusters O
of O
symptoms O
consistent O
with O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
, O
including O
hyperhidrosis B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
and O
yawning B-NonOSE_AE
have O
occurred O
in O
patients O
treated O
with O
MOVANTIK O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
addition O
, O
patients O
receiving O
methadone O
as O
therapy O
for O
their O
pain B-Not_AE_Candidate
condition O
were O
observed O
in O
clinical O
trials O
to O
have O
a O
higher O
frequency O
of O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
that O
may O
have O
been O
related O
to O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
than O
patients O
receiving O
other O
opioids O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Patients O
having O
disruptions B-Not_AE_Candidate
to I-Not_AE_Candidate
the I-Not_AE_Candidate
blood I-Not_AE_Candidate
- I-Not_AE_Candidate
brain I-Not_AE_Candidate
barrier I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
or O
reduced B-NonOSE_AE
analgesia I-NonOSE_AE
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
MOVANTIK O
in O
such O
patients O
. O

Monitor O
for O
symptoms O
of O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
in O
such O
patients O
. O

